Creative Planning’s Context Therapeutics CNTX Stock Holding History

Creative Planning’s Portfolio CNTX Stock Details CNTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$4.63K	Buy	+15,398	New	+$7.6K	﹤0.01%	4344

Other funds holding CNTX

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Russell Investments Group London, United Kingdom $114B AUM 33.83% 1-Year Est. Return

Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return

TGY2IT

Timothy G. Youngquist 2020 Irrevocable Trust Fort Myers, Florida $530M AUM 95.29% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Clear Harbor Asset Management Stamford, Connecticut $1.74B AUM 28.15% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return

Natixis Paris, France $28B AUM 27.03% 1-Year Est. Return

Axxcess Wealth Management Carlsbad, California $2.44B AUM 16.42% 1-Year Est. Return

Citigroup New York $308B AUM 40.94% 1-Year Est. Return

Creative Planning's CNTX Position: Q3 2026 in Review

Creative Planning opened a new position in Context Therapeutics (CNTX) in Q3 2026: 15,398 shares worth $4.63K. The stake represents ﹤0.01% of the portfolio and ranks #4344 among its holdings.

24 funds tracked by Wall St. Rank hold CNTX as of Q3 2026.

Creative Planning held 15,398 shares of Context Therapeutics worth $4.63K as of Q3 2026.
Context Therapeutics was a new Creative Planning position in Q3 2026.
Context Therapeutics made up ﹤0.01% of Creative Planning's portfolio in Q3 2026, its #4344 holding.
24 funds tracked by Wall St. Rank held Context Therapeutics as of Q3 2026.

Based on Creative Planning's 13F filing for Q3 2026, filed 2 Nov 2026.